What's in Casa Sollievo della Sofferenza IRCCS's pipeline?

Casa Sollievo della Sofferenza IRCCS has 4 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Casa Sollievo della Sofferenza IRCCS's portfolio?

Top competitors by shared drug class: Arbutus Biopharma Corporation, Australasian Gastro-Intestinal Trials Group, Beijing 302 Hospital, Brooke Army Medical Center, Hepatitis Resource Network.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/casa-sollievo-della-sofferenza-irccs.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Casa Sollievo della Sofferenza IRCCS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Casa Sollievo della Sofferenza IRCCS pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Peginterferon alpha-2a + Ribavirin	Peginterferon alpha-2a + Ribavirin	phase 3	Antiviral		Infectious Diseases
Peg Interferon alpha2b + Ribavirin	Peg Interferon alpha2b + Ribavirin	phase 3	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase	Virology/Hepatology

Therapeutic area mix

Infectious Diseases · 1
Virology/Hepatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Arbutus Biopharma Corporation · 1 shared drug class
Australasian Gastro-Intestinal Trials Group · 1 shared drug class
Beijing 302 Hospital · 1 shared drug class
Brooke Army Medical Center · 1 shared drug class
Hepatitis Resource Network · 1 shared drug class
Hospices Civils de Lyon · 1 shared drug class
Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Casa Sollievo della Sofferenza IRCCS:

Cite this brief

Drug Landscape (2026). Casa Sollievo della Sofferenza IRCCS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/casa-sollievo-della-sofferenza-irccs. Accessed 2026-05-17.